Seer Board Reviews Competing Takeover Bids from Activists and Its Own CEO
Seer confirms two revised unsolicited offers: $2.55 + CVR from Radoff-JEC Group and $2.45 + two CVRs from CEO Farokhzad. Special committee reviewing.
/ 1648 items
#XY↓
Abivax Gets Positive FDA Feedback, Stays on Track to File for New Ulcerative Colitis Drug by End of 2026
Abivax completes positive pre-NDA meeting with FDA for obefazimod in ulcerative colitis, stays on track for 2026 filing, with $3-5B peak sales potential.
FDA Panel Backs Replimune’s Melanoma Drug After Multiple Rejections
FDA panel votes 10-3 for Replimune’s RP1 melanoma drug after two rejections, citing benefits for resistant patients despite messy data.
Karyopharm Shares Plunge After Selinexor Misses in Endometrial Cancer Trial
Karyopharm seeks accelerated FDA approval for selinexor combined with ruxolitinib—the potential first novel combo therapy for myelofibrosis patients.
Alnylam Stock Crashes Nearly 30% as Company Lowers Full-Year Revenue Outlook
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.
Teladoc Cuts 2026 Outlook as BetterHelp Cash-Pay Demand Weakens
Teladoc reported Q2 revenue of $606.9M (down 4%), missing estimates. BetterHelp struggles led to a full-year guidance cut.